AB AB Science SA

AB Science announces that results from masitinib study AB07015 in severe asthma have been selected for presentation at an ATS symposium held on 16th October, 2020

AB Science announces that results from masitinib study AB07015 in severe asthma have been selected for presentation at an ATS symposium held on 16th October, 2020
EN
13/10/2020

Underlying

ABAB Science SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AB Science SA

 PRESS RELEASE
Free
AB AB SCIENCE SA

AB Science announces the successful completion of a EUR 2.8 million pr...

AB Science announces the successful completion of a EUR 2.8 million private placement PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.8 MILLION PRIVATE PLACEMENT AB SCIENCE IS FULLY FINANCED TO FINISH PHASE 1 OF AB8939 IN AML AND TO EXECUTE AN EXPANSION PHASE TO MAXIMIZE CHANCE OF SUCCESS OF FUTURE REGISTRATION STUDY Paris, October 17, 2025, 8am AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 2.8 million subscribed by a limited number of in...

October 17, 2025 1 EN
 PRESS RELEASE
Free
AB AB SCIENCE SA

AB Science annonce le succès d'un placement privé de 2,8 millions d'eu...

AB Science annonce le succès d'un placement privé de 2,8 millions d'euros COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE SUCCES D’UN PLACEMENT PRIVE D’ENVIRON 2,8 MILLIONS D’EUROS AB SCIENCE EST ENTIEREMENT FINANCEE POUR TERMINER LA PHASE 1 DE L'ETUDE AB8939 DANS LA LMA ET POUR EXECUTER UNE PHASE D'EXPANSION DESTINEE A MAXIMISER LES CHANCES DE SUCCES DE LA FUTURE ETUDE D'ENREGISTREMENT Paris, 17 octobre 2025, 8h AB Science S.A. (la “Société” ou “AB Science”, Euronext – FR0010557264 – AB) annonce aujourd'hui le succès d'une augmentation de capital d'un montant brut total de 2,8 millions d’eu...

October 17, 2025 1 EN
 PRESS RELEASE
Free
AB AB SCIENCE SA

AB Science provides intitial Phase 1 data for the combination of AB893...

AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia PRESS RELEASE AB SCIENCE PROVIDES INITIAL PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA Paris, 16 October 2025, 9pm CET AB Science SA (Euronext - FR0010557264 - AB) today provides an update on its AB8939 program in acute myeloid leukemia (AML). The webcast presentation is available on the company’s website, in the section « Press Releases »:  Highlights o...

October 16, 2025 1 EN
 PRESS RELEASE
Free
AB AB SCIENCE SA

AB Science présente les premières données de phase 1 de la combinaison...

AB Science présente les premières données de phase 1 de la combinaison d’AB8939 et du venetoclax dans le traitement de la leucémie myéloïde aiguë réfractaire ou en rechute COMMUNIQUÉ DE PRESSE AB SCIENCE PRESENTE LES PREMIÈRES DONNÉES DE PHASE 1 DE LA COMBINAISON D’AB8939 ET DU VENETOCLAX DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË RÉFRACTAIRE OU EN RECHUTE Paris, le 16 octobre 2025, 21h00 AB Science SA (Euronext - FR0010557264 - AB) fait aujourd'hui le point sur le programme d’AB8939 dans le traitement de la leucémie aiguë myéloïde (LMA). La présentation de la conference virtuell...

October 16, 2025 1 EN
 PRESS RELEASE
Free
AB AB SCIENCE SA

AB Science will hold a virtual conference on Thursday, October 16, 202...

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939 PRESS RELEASE AB SCIENCE RELEASES INITIAL DATA ON THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA (AML): THE FIRST THREE PATIENTS, ALL OF WHOM HAVE AML WITH VERY UNFAVORABLE GENETIC PROFILES, ARE RESPONDING TO TREATMENT The combination treatment is well-tolerated, with no hematological toxicityThe disease control rate is 100% (3/3)The partial response rate is 100% (3/3), including one...

October 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch